Neuromedin - instructions for use, doses, side effects, contraindications

Active substanceIpidacrinIpidacrin

Similar drugsTo uncover

Axamon®

solution w / m PC

PIK-PHARMA, LLC Russia

Axamon®

pills inwards

PIK-PHARMA, LLC Russia

Ipigrix®

solution w / m PC

GRINDEX, JSC Latvia

Ipigrix®

pills inwards

GRINDEX, JSC Latvia

Neuromidine®

pills inwards

Olainfarm, AO Latvia

Neuromidine®

solution w / m PC

Olainfarm, AO Latvia

Dosage form: & nbspsolution for intramuscular and subcutaneous administration

Composition:1 ml of the preparation contains:

active substance: ipidacrine hydrochloride monohydrate (in terms of ipidacrine hydrochloride) 5 mg or 15 mg;

Excipients: hydrochloric acid concentrated to pH 3.0, water for injection up to 1.0 ml.

Description: A clear, colorless liquid.

Pharmacotherapeutic group:Cholinesterase inhibitor

ATX: & nbsp

N.07.A.A Anticholinesterase drugs

Pharmacodynamics:

Neuromidine® - has a direct stimulating effect on impulse conduction on nerve fibers, interneuronal and neuromuscular synapses of the peripheral and central nervous system.

pharmachologic effect Neuromidine® based on a combination of two mechanisms of action:

- blockade of the potassium channels of the membrane of neurons and muscle cells;

- reversible inhibition of cholinesterase in synapses.

Neuromidine® strengthens the action on smooth muscles not only acetylcholine, but also adrenaline, serotonin, histamine and oxytocin.

Neuromidine® has the following pharmacological effects:

- improves and stimulates impulse in the nervous system and neuromuscular transmission;

- strengthens the contractility of smooth muscle organs under the influence of agonists acetylcholine, adrenaline, serotonin, histamine and oxytocin receptors, with the exception of potassium chloride;

- improves memory, inhibits the progressive course of dementia.

At preclinical examination Neuromidine® had no teratogenic, embryotoxic, mutagenic, carcinogenic and immunotoxic effects, did not affect the endocrine system.

Pharmacokinetics:

With subcutaneous or intramuscular injection, Neuromidine^®quickly absorbed after administration. The maximum concentration in the blood is reached after 25-30 minutes after administration. 40-55% of the active substance binds to blood plasma proteins. Neuromidine^® quickly enters the tissues; half-distribution period is 40 minutes. Metabolised in the liver. The drug is excreted through the kidneys, as well as extrarenally (through the gastrointestinal tract).Half-life of the drug Neuromidin^® with parenteral administration is 2-3 hours. Excretion of Neuromidine^® kidneys occurs mainly through tubular secretion, and only 1/3 of the drug is secreted by glomerular filtration. After parenteral administration, 34.8% of the dose is excreted unchanged in the urine.

Indications:

Diseases of the peripheral nervous system: mono- and polyneuropathy, polyradiculopathies, myasthenia gravis and myasthenic syndrome of various etiologies. Diseases of the central nervous system: bulbar paralysis and paresis; the recovery period of organic lesions of the central nervous system, accompanied by motor disorders.

Contraindications:

Hypersensitivity to any of the components of the drug, epilepsy, extrapyramidal diseases with hyperkinesia, angina and pronounced bradycardia, bronchial asthma, mechanical obstruction of the intestine or urinary tract, vestibular disorders, peptic ulcer of the stomach or duodenum in the acute stage, pregnancy (the drug raises the tone of the uterus) and lactation period.

Children under 18 years (no systematic data on the application).

Carefully:

With peptic ulcer of stomach and duodenum, thyrotoxicosis, diseases of the cardiovascular system, as well as patients with obstructive diseases of the respiratory system in the history or in acute respiratory diseases.

Dosing and Administration:

Subcutaneously or intramuscularly. Doses and duration of treatment are determined individually, depending on the severity of the disease.

Diseases of the peripheral nervous system:

Mono-and polyneuropathy of different genesis: subcutaneously and intramuscularly 5-15 mg 1 - 2 times a day, course 10-15 days (in severe cases - up to 30 days); further treatment continues with the tablet form of the drug.
Myasthenia gravis and myasthenic syndrome: subcutaneously or intramuscularly 15-30 mg, 1-3 times a day, with a further transition to the tablet form. The general course of treatment is 1-2 months. If necessary, treatment can be repeated several times with a break between courses in 1-2 months.

Diseases of the central nervous system:

Bulbar paralysis and paresis: subcutaneously and intramuscularly 5-15 mg 1 - 2 times a day 10-15 days; if possible, switch to a tablet form
Rehabilitation for organic lesions of the central nervous system: intramuscularly 10-15 mg 1-2 times a day, course up to 15 days further, if possible, go to the tablet form.

Side effects:

Caused by excitation of m-holinoretseptorov: drooling, enhanced sweating, palpitation, nausea, diarrhea, jaundice, bradycardia, epigastric pain, increased secretion of bronchial secretions, convulsions. Salivation and bradycardia can be reduced by m-holinoblokatorami (atropine and etc.).

Less often, after using higher doses, dizziness, headache, vomiting, general weakness, drowsiness, skin-allergic reactions (pruritus, rash) were observed. In these cases, reduce the dose or briefly (for 1-2 days) interrupt the reception of the drug. These side effects are observed in less than 10% of patients.

Overdose:

Symptoms: loss of appetite, bronchospasm, lachrymation, increased sweating, narrowing of the pupils, nystagmus, increased peristalsis of the gastrointestinal tract, spontaneous defecation and urination, vomiting, jaundice, bradycardia, intracardiac conduction disorders, arrhythmias, lowering blood pressure, anxiety, anxiety, arousal, feeling fear, ataxia, convulsions, coma, speech disorders, drowsiness and general weakness.

Treatment: use symptomatic therapy, use m-holinoblokatory. atropine, cyclodol, metacin, and others.

Interaction:

Neuromidine® enhances sedation in combination with drugs that depress the central nervous system.

Effects and side effects are enhanced when combined with other cholinesterase inhibitors and M-cholinomimetic agents.

In patients with myasthenia gravis, the risk of developing a cholinergic crisis increases, if you apply NeuromidineSimultaneously with other cholinergic agents.

The risk of bradycardia increases if β-blockers were used before the drug was started Neuromidine.

Neuromidine® can be used in combination with cerebrolysin.

Alcohol increases the side effects of the drug.

Special instructions:There are no systematized data on the use of the parenteral form of Neuromidine ® in children.

Effect on the ability to drive transp. cf. and fur:

During treatment it is necessary to refrain from driving by car, and also employment by potentially dangerous kinds of activity requiring an increased concentration of attention and speed of psychomotor reactions.

Form release / dosage:

Solution for intramuscular and subcutaneous administration, 5 mg / ml and 15 mg / ml.

Packaging:

1 ml of the drug in neutral glass ampoules (type I).

10 ampoules per contour cell pack of polyvinylchloride film.

On 1 contour acheikova packing together with the instruction on application place in a pack from a cardboard.

Storage conditions:

In the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:П N014238 / 02

Date of registration:26.11.2007 / 15.02.2017

Expiration Date:Unlimited

The owner of the registration certificate:Olainfarm, AOOlainfarm, AO Latvia

Manufacturer: & nbsp

Olainfarm, AO

SOPHARMA, AD Bulgaria

Representation: & nbspOLAINFARM JSC OLAINFARM JSC Latvia

Information update date: & nbsp27.06.2018

Illustrated instructions

Instructions

Neuromidine® (Neuromidin®)